<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20260212</date><key>collection.key</key><document><id>PMC12807502</id><infon key="license">CC BY-NC</infon><passage><infon key="alt-title">Emu Oil as a Potential Adjunct in IBD Treatment</infon><infon key="article-id_doi">10.1159/000549758</infon><infon key="article-id_pmc">PMC12807502</infon><infon key="article-id_publisher-id">549758</infon><infon key="fpage">53</infon><infon key="issue">1</infon><infon key="kwd">Emu oil Adjunct therapy Inflammatory bowel disease Fatty acids Ulcerative colitis Crohn’s disease</infon><infon key="license">This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (https://karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.</infon><infon key="lpage">64</infon><infon key="name_0">surname:Mhlanga;given-names:Sisanda Nomcebo</infon><infon key="name_1">surname:Howarth;given-names:Gordon Stanley</infon><infon key="name_2">surname:Mashtoub;given-names:Suzanne</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords</infon><infon key="type">front</infon><infon key="volume">11</infon><infon key="year">2026</infon><offset>0</offset><text>Emu Oil: A Potential Adjunct to Inflammatory Bowel Disease Treatment?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>70</offset><text>Abstract</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>79</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>90</offset><text>Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic lifelong condition that affects the colon to a variable extent. Current treatments for IBD include aminosalicylate-based drugs, corticosteroids, antibiotics, immunomodulators, biologics, other small-molecule drugs, and surgical intervention. Nonetheless, treatment options are variably effective, associated with serious side effects, and often leave individuals at risk of relapse.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>575</offset><text>Summary</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>583</offset><text>In this narrative review, we explore emu oil (EO), a naturally sourced agent, that may be utilised to broaden therapeutic options in IBD. The anti-inflammatory, antioxidant, reparative, and protective properties of EO have been attributed to its unique blend of fatty acids and non-triglyceride fraction. To date, several preclinical trials of orally administered EO have demonstrated these properties in a range of intestinal inflammatory conditions, showing reduced inflammation and mucosal damage, together enhancing intestinal healing.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1123</offset><text>Key Messages</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1136</offset><text>While EO remains an interesting candidate for future investigations, current knowledge is limited to animal models and its clinical relevance is yet to be defined. Well-designed clinical trials will be essential to determine the safety and efficacy of EO before it can be considered as a potential adjunct to conventional therapy for IBD.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1475</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1488</offset><text>Inflammatory bowel disease (IBD) is a collective term used to describe chronic, idiopathic, and incurable intestinal inflammatory disorders termed Crohn’s disease (CD) and ulcerative colitis (UC). CD is characterised by discontinuous transmural inflammation that can affect the entire gastrointestinal tract. In contrast, UC is limited to the colon, with superficial mucosal inflammation in a continuous pattern.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1903</offset><text>The aetiology of IBD remains elusive; however, it is thought that the complex interaction between several factors, including genetic susceptibility, intestinal microbiota dysbiosis, external environment, and heightened immune responses, impacts mucosal homeostasis in the intestine. IBD, commonly diagnosed in adolescence or early adulthood, is a progressive disease due to cumulative relapsing and remitting inflammation in the intestine. Current treatment options are variably effective, generally not curative and accompanied by serious side effects. Therefore, early and effective management that balances safety is crucial to improve clinical outcomes. In this narrative review, we explore the potential for emu oil (EO) to augment conventional IBD treatment, based on its anti-inflammatory, antioxidant, and reparative properties in pre-clinical studies.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>2764</offset><text>IBD Treatment Options</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>2786</offset><text>First-line therapy used to treat mild to moderate IBD consists of anti-inflammatory drugs that contain 5-aminosalicylic acid, followed by corticosteroids in severe IBD or to induce remission in active disease. The main adverse side effects associated with aminosalicylate-based agents include pancreatitis, cardiotoxicity, hepatorenal toxicity, and sexual dysfunction. Furthermore, though corticosteroids have superior clinical efficacy to aminosalicylate-based drugs, long-term use of corticosteroids is associated with adverse effects and complications such as glaucoma and hypertension. In addition, antibiotics are often used in steroid-refractory IBD to treat bacterial overgrowth; however, they can also increase dysbiosis and antibiotic resistance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3542</offset><text>Second-line treatment escalation consists of immunomodulators (thiopurines) and biologics (targeting numerous cytokines including tumour necrosis factor-alpha [TNF-α], interleukin [IL]-23, and IL-12). Immunomodulators may contribute to a range of side effects such as pancreatitis and pneumonitis, while biologics, such as infliximab and adalimumab, are associated with an increased risk of serious infections, malignancies, and safety concerns, including infusion reactions. Multiple novel small-molecule drugs are also available for IBD treatment, including selective Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators, SMAD7 antisense oligonucleotide, and PDE4 inhibitors. These options offer convenient administration methods, are non-immunogenic, low-cost, and have short half-lives. Nevertheless, these options still present with serious adverse side effects and often IBD sufferers remain at risk of recurrence. Surgical intervention involving colectomy may be necessary for individuals who are unresponsive to medical treatment. Therefore, novel therapeutic or adjunctive strategies are desirable.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4670</offset><text>Emu Oil as a Functional Nutraceutical in Gastrointestinal Inflammation</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4741</offset><text>Naturally sourced agents, such as the nutraceutical EO, have garnered attention due to their promising preclinical findings. EO has been used for thousands of years by Australia’s First Nations Peoples to alleviate inflammation, pain from various musculoskeletal disorders, and to treat burns and wounds. EO is derived from the subcutaneous and retroperitoneal adipose tissue of the emu (Dromaius novaehollandiae) bird, the only extant emu species, native to mainland Australia. Preparation of EO involves rendering macerated tissue into liquified fat, undergoing a series of filtration processes to extract purified oil. More recently, experimental models of intestinal inflammation have displayed attenuated inflammatory responses, reduced mucosal damage, and increased healing rates following oral administration of EO, although its mechanism of action remains unclear.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5616</offset><text>Emu Oil Composition</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5636</offset><text>Fatty acids (FAs) are the predominant component in EO, constituting 98.8% of subcutaneous and 98.0% of retroperitoneal adipose tissue. Typically, EO is composed of monounsaturated (42% oleic acid [18:1 n-9]), polyunsaturated (21% linoleic acid [18:2 n-6] and 1% α-linolenic acid [18:3 n-3]), saturated (21% palmitic acid [16:0]) FAs and a small proportion of other FAs depending on environmental, genetic, and oil processing factors (Table 1). For instance, linoleic acid may undergo thermally induced isomerisation to trans-linoleic acid; therefore, this form may be present in some EO batches. Other potential FAs that may be present in minute levels include heptadecanoic, lignoceric, behenic, myristoleic, hexadecenoic, heptadecenoic, vaccenic, elaidic, petroselinic, eicosapentaenoic (EPA), docosahexaenoic (DHA), hexadecadienoic, rumenic, eicosatrienoic, and docosapentaenoic acid. The remaining 1–2% of EO is composed of a minor non-triglyceride fraction, containing variable levels of antioxidant bioactive compounds including carotenoids (vitamin A), flavones, polyphenols, phospholipids, tocopherols (vitamin E), and vitamin D.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>6778</offset><text>Composition of FAs in orally administered EO across different experimental studies</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Common names&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lindsay et al. (2010)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abimosleh et al. (2012)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mashtoub et al. (2013)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sethuraman et al. (2015)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Vemu et al. (2016)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chartier et al. (2018)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mashtoub et al. (2018)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Safaeian et al. (2019)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mitchell et al. (2020)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chartier et al. (2021)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mashtoub et al. (2022)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td colspan=&quot;12&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Saturated&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Palmitic acid 16:00&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20.76&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23.87&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23.6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22.7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Stearic acid 18:00&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.17&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7.09&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.76&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Arachidic acid 20:00&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.11&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Myristic acid 14:00&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.09&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.71&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.0&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;12&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Monosaturated&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Palmitoleic acid 16:1 n-7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.08&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.47&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.73&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Vaccenic acid 18:1 n-7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.19&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Oleic acid 18:1 n-9&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48.02&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48.0&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35.61&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41.84&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36.4&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gondoic acid 20:1 n-9&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.33&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.4&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;12&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Polyunsaturated&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Linoleic acid 18:2 n-6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7.74&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7.7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21.35&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.43&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.0&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14.3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;α-Linolenic acid 18:3 n-3&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.69&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.28&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.29&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.4&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.4&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.9&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Eicosadienoic acid 20:2 n-6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.06&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA 20:4 n-6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;​&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>6861</offset><text>Common names	Lindsay et al. (2010)	Abimosleh et al. (2012)	Mashtoub et al. (2013)	Sethuraman et al. (2015)	Vemu et al. (2016)	Chartier et al. (2018)	Mashtoub et al. (2018)	Safaeian et al. (2019)	Mitchell et al. (2020)	Chartier et al. (2021)	Mashtoub et al. (2022)	 	Saturated	 	Palmitic acid 16:00	25.8	25.8	24	20.76	23.87	24.1	24	23.6	22.7	21.2	24.1	 	Stearic acid 18:00	10.17	10.2	8.5	7.09	10.76	9.8	8.5	9.8	12.7	11.8	9.8	 	Arachidic acid 20:00	0.11	0.1	​	​	​	0.1	​	0.1	0.2	0.1	0.1	 	Myristic acid 14:00	​	​	​	2.09	0.71	0.3	​	0.3	5.0	6.2	0.3	 	Monosaturated	 	Palmitoleic acid 16:1 n-7	4.08	4.1	4.3	2.47	4	4.73	4.3	4.1	6.3	2.8	4	 	Vaccenic acid 18:1 n-7	2.19	2.2	​	​	2.6	​	​	2.2	3	2.6	2.6	 	Oleic acid 18:1 n-9	48.02	48.0	49.1	35.61	48.8	41.84	49.1	48.2	36.4	32.2	48.8	 	Gondoic acid 20:1 n-9	0.33	0.3	​	​	0.3	​	​	0.3	0.4	0.5	0.3	 	Polyunsaturated	 	Linoleic acid 18:2 n-6	7.74	7.7	9.5	21.35	12.43	9.3	​	10.0	8	14.3	9.3	 	α-Linolenic acid 18:3 n-3	0.69	0.7	1.1	1.28	0.29	0.4	1.1	0.4	0.9	0.7	0.4	 	Eicosadienoic acid 20:2 n-6	0.06	​	​	​	​	0.1	​	0.1	0.8	1.1	0.1	 	AA 20:4 n-6	​	​	​	​	​	0.1	​	0.1	0.8	1.2	0.1	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>8029</offset><text>Animal models have assessed the effects of EO in both healthy rodents and those induced with gastrointestinal inflammatory disorders, including UC, Crohn’s-like colitis, CA-CRC, and chemotherapy-induced mucositis. Values are expressed as percentages (%).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8286</offset><text>Factors Affecting the Composition of Emu Oil</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8331</offset><text>As the FA profile of EO is influenced by both emu feed composition and processing methods, these factors can be strategically modified to optimise the oil’s composition and biological potency. A study by Beckerbauer et al. (2001) demonstrated the influence of soybean oil feed and tallow feed on EO composition. After 13 weeks, soybean oil-fed emus produced oil that contained higher concentrations of polyunsaturated FAs than tallow-fed emus.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8777</offset><text>Snowden and Whitehouse (1997) demonstrated that varying preparations of topically applied EO further influenced their efficacy when treating inflammation in experimental polyarthritis in rats. EO samples varied in their additives, whether the oil was derived from subcutaneous or intraperitoneal adipose tissue, bird origin (Western Australian or Queensland), commercially available or laboratory prepared, oil rendering processes, and storage. Nonetheless, a single study exploring three different sources and batches of orally administered EO concluded that the therapeutic benefit did not differ significantly in a mouse model of chemotherapy-induced mucositis. Specifically, two samples were different batches sourced from the same Australian company, while the third sample was sourced from a second Australian company. Moreover, studies have identified that varying oil extraction methods result in differences in physical properties, including oiliness, viscosity, density in the liquid state, colour, and refraction index. Future studies should integrate compositional, physicochemical, and biological analyses to determine if production can be optimised to yield consistent and potent formulations for use in IBD.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10000</offset><text>Emu Oil Quality Control</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10024</offset><text>To date, few studies have explored the quality control of EO, including its physical, rheological, toxicological properties, and chemical characterisation. Koshiishi et al. (2022) characterised the carcass traits and fat quality from breeding emus in Northern Japan and found that fat yield was greater in males compared to females; however, there was no significant difference in oil composition and fat melting point. A relationship between fat melting point and FA composition was confirmed, with lower melting points indicating oil that is relatively rich in unsaturated FAs. Buclaw et al. demonstrated that fat from 15-year-old emus was composed of a greater proportion of unsaturated FAs and minerals, including potassium, phosphorus, magnesium, iron, zinc, lead, selenium, chromium, and cadmium, compared to birds 1 year and 3 years of age. Though older emus may be advantageous by producing higher levels of unsaturated FAs, higher mineral content is undesirable due to potential toxicity and their catalytic effect on fat oxidation during storage and processing. Additionally, fat from older emus tended to have a higher water and protein content, which would also lower the fat melting point, with a decreased overall fat content and increased rancidification. Sex particularly influenced mineral content, with silicon, calcium, copper, and strontium levels higher in the adipose tissue of males. Further investigations on the effects of intrinsic characteristics, including sex, age, and genetics, on emu fat quality and, consequently, the quality of the extracted oil, are necessary to inform and standardise oil preparation procedures.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11673</offset><text>Emu Oil in Comparison to Other Ratite Oils</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11716</offset><text>The emu belongs to a group of flightless birds, termed ratites, with raft-like breastbones devoid of a keel. This group further encompasses the African ostrich (Struthio camelus), native to Africa; three kiwi species (Apterix sp.), native to New Zealand; the cassowary (Casuarius sp.), native to New Guinea; the rhea ostrich (Rhea americana) and the choique (Pterocnemia pennata), both native to South America.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12127</offset><text>A study by Bennett et al. comparing the antioxidant properties of ratite oils and avian oils found that ratite oils significantly decreased peroxidation of erythrocyte membranes, of which EO was the most effective. The ability of EO to protect against oxidative damage is suggested to be related to its high unsaturated-to-saturated FA ratio. Moreover, the free radical scavenging properties of EO are believed to be linked to its non-triglyceride fraction. Another study observed the impact of different topically applied naturally derived oils on ear inflammation. The FA composition in EO did not vary profoundly compared to fish, flaxseed, olive, and liquified chicken fat oil; however, the anti-inflammatory effects were more pronounced following EO application. Thus, the anti-inflammatory properties of EO are likely not fully conferred by the FA profile alone. EO has also demonstrated antimicrobial properties, which may be useful in candida infections.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>13090</offset><text>Safety of Orally Administered Emu Oil</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13128</offset><text>EO is a readily available concentrated oil (100% pure EO) approved by the Australian Therapeutic Goods Administration (TGA). EO is also marketed in the USA and Europe as a dietary supplement, nutritional food and for topical skincare usage. However, toxicology and pharmacology studies are lacking since most studies have focused on the efficacy rather than the safety of orally administered EO. Nonetheless, Lan et al. chemically characterised EO and evaluated in vivo toxicology in mice. Importantly, the study demonstrated that orally administered EO at dose rates up to 20 mL/kg bodyweight did not increase the frequency of micronucleated polychromatic erythrocytes, nor rates of immature erythrocytes to total erythrocytes, suggesting an absence of cytotoxic effects. Additionally, a bacterial reverse mutation assay was conducted, assessing whether bacterial colonies underwent a mutation reversing a previous mutation, allowing the bacteria to regain the ability to grow in a specific condition. EO did not increase the number of revertant bacterial colonies, displaying the non-mutagenic activity of EO. An in vitro chromosome aberration assay, used to investigate potential chromosome breakages attributed to different EO dosages (1.25, 2.5, and 5 μg/mL), found no aberrations from any of the EO treatment groups. Furthermore, a single orogastric gavage of EO at a dose of 9.3 mg/mL did not affect bodyweight in mice.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14556</offset><text>In humans, current standard dosing for “maintained well-being” of orally administered EO is 2–3 capsules once to thrice daily according to manufacturer’s recommendation (Emu Tracks, 2025) typically containing between 750 to 1,000 mg of oil. Although EO presents a low health hazard and is like most animal fats, it readily metabolises; to date, no published studies have explored its pharmacokinetics and pharmacodynamics. The TGA has noted that the pharmacokinetic properties of EO are typical of other triglycerides and the available data indicate that EO would undergo emulsification, enzymatic transformation, absorption, and metabolism like other edible fats and oils. Nonetheless, the paucity of clinical studies investigating orally administered EO limits our understanding of optimal dosing and safety profiles in IBD patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>15400</offset><text>Clinical Trials of Topical Emu Oil Application</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15447</offset><text>Protective, Reparative, and Anti-Inflammatory Properties</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15504</offset><text>Currently, there are limited therapeutic agents that can promote mucosal healing and thus tissue damage in the gastrointestinal tract of IBD patients persists, even in those who have achieved clinical remission. Importantly, numerous studies have documented the ability of EO to promote epithelial repair. A clinical trial by Lagniel and Torres (2007) demonstrated the reparative properties of topically-applied EO, illustrating improved recovery of damaged skin in children with second- and third-degree burn injuries caused by fire and scalding water. Moreover, topical application of EO accelerated re-epithelisation and epidermal differentiation, increased follicle restoration, wound contraction, and keratinisation in experimental models. Overall, it has been noted that EO can penetrate dermal layers and prevent cell damage because of the α-linolenic and oleic FA content, which aids in the structure and function of cell membranes in the skin barrier.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16469</offset><text>Topically applied EO has also demonstrated the ability to significantly decrease serum cytokines IL-4 and IL-14 in a mouse model of atopic dermatitis. EO further decreased tissue cytokines TNF-α by 60% and IL-1α by 70% in an experimental model of inner ear inflammation. The systemic and local anti-inflammatory effect of EO may be more pronounced when orally administered. Evidence suggests the reparative properties of topically applied EO are also attributed to immune micromanagement through the secretion of anti-inflammatory cytokines such as IL-10, downregulation of pro-inflammatory cytokines including IL-1β, inhibition of inflammatory pathways including JNK and p38 signalling pathways, and the promotions of M2 macrophage polarization.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>17227</offset><text>Preclinical Studies of Orally Administered Emu Oil in Gastrointestinal Disorders</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>17308</offset><text>Intestinal Repair Properties of Emu Oil</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>17348</offset><text>Experimental models have illustrated the protective and reparative properties of orally administered EO in gastrointestinal inflammation. In a 10-day study, daily oral administration of EO reduced tissue damage in rats with dextran sulphate sodium (DSS)-induced colitis. EO promoted crypt lengthening in the proximal colon and increased crypt depth in the distal colon, supporting a role in intestinal repair through mucosal growth. A similar 49-day study demonstrated significantly decreased disease activity index (DAI) scores (encompassing bodyweight loss, stool consistency, rectal bleeding and general conditions) following EO treatment in mice with DSS-induced colitis. However, EO did not contribute to further crypt lengthening. Crypt lengthening is thought to represent a compensatory mechanism following the loss of crypts due to intestinal damage. EO may therefore accelerate the beginning stages of these repair processes, displayed in the acute model of DSS-induced colitis. Further studies would benefit from time interval assessments of crypt lengthening attributed to EO administration.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>18451</offset><text>Histological damage severity encompasses crypt depth and crypt disruption, goblet cell number reduction, lymphocytic and polymorphonuclear infiltration, and thickening or oedema of the submucosa and muscular externa. Following oral EO administration, histological damage severity scores were significantly reduced in the distal colon of DSS-diseased mice compared to DSS controls. These outcomes were consistent with an earlier study, which also noted significantly reduced histological severity scores in the proximal and distal colon following EO administration. Orally administered EO in rats with acetic acid-induced colitis has additionally demonstrated the ability to reduce macroscopic lesion scores (encompassing ulcers in the mucosal surface of the colon and necrotic areas) and histological damage severity scores. Nonetheless, there are several limitations in these DSS-colitis model studies that need to be acknowledged. While the chronic DSS-induced mouse model replicates several clinical and histopathological features of UC, it does not fully capture the complexity and multifactorial nature of the human disease, including immune, genetic, and microbial interactions. Furthermore, many of these studies rely heavily on histological, behavioural, and biochemical endpoints at a single terminal point rather than including longitudinal assessments. Gaining this information would provide further insights into the temporal effects of EO on inflammation and repair.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>19931</offset><text>In a trinitrobenzene sulfonic acid-induced Crohn’s-like colitis rodent model, orally administered EO decreased damage severity scores. EO-treated animals exhibited reduced histological damage to the colonic mucosa compared to disease controls at the end of the trial (day 6), potentially due to the antioxidant scavenging abilities of EO. In another Crohn’s-like colitis model, oral administration of EO provided partial intestinal protection by reducing intestinal ulceration significantly compared to the diseased controls. Interestingly, EO administration improved ulceration to a greater extent compared to the sulfasalazine-treated group. However, the short trial duration of most animal model studies limits the ability to assess the long-term effects of EO on the relapsing and remitting course of IBD. Nonetheless, EO may facilitate intestinal repair processes through crypt cell proliferation (hyperplasia), decreased apoptosis, cell hypertrophy, or a combination of all three processes, contributing to intestinal adaptations. Two independent preclinical trials confirmed these claims with the oral administration of EO in healthy rats, resulting in ileal mucosal thickening. Following the cessation of EO treatment, normal villus height and crypt length ratios and dynamics were restored. The duration of EO administration in these studies was short. In the context of intestinal disorders, long-term use of EO improved damage severity scores in experimental colitis. Observing the long-term use of EO in healthy animals may be beneficial in confirming safety.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>21507</offset><text>5-Fluorouracil (5-FU) preferentially damages the proximal small intestine (jejunum) due to the higher cell turnover rate in this region. Several studies in rodents with 5-FU-induced mucositis illustrate that EO contributes significantly to mucosal thickening through increasing villus height and crypt depth in the small intestine, particularly in the jejunum and ileum, compared to 5-FU controls. Furthermore, 5-FU significantly decreased the number of mucin-secreting goblet cells in the jejunum and ileum, which was subsequently ameliorated following EO administration in the ileum. This suggests the role of EO in strengthening intestinal barrier function.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>22168</offset><text>Oral administration of EO has also attenuated disease parameters in preclinical models of colitis-associated colorectal cancer (CA-CRC). Importantly, in a 9-week trial, Chartier et al. (2018) demonstrated that orally administered EO in azoxymethane/DSS-induced CA-CRC in mice did not affect crypt depth, therefore not contributing to uncontrolled proliferation of intestinal epithelium. Moreover, EO decreased disease activity in mice with CA-CRC. EO-treated mice displayed fewer small tumours, whereas Mashtoub et al. (2022) demonstrated that EO reduced the number of large colonic tumours in a 12-week trial. Similarly, Chartier et al. (2021) noted an overall reduction in numbers of colonic tumours in mice CA-CRC following EO gavage. Data on the effect of EO on healthy controls and azoxymethane/DSS-induced CA-CRC controls imply that the intestinal growth process promoted by EO is controlled and does not contribute to colonic neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>23112</offset><text>Ki-67 is a proliferative marker, with expression increased in many types of cancers. Interestingly, in a murine model of CA-CRC, orally administered EO reduced Ki-67 expression, further suggesting that EO does not contribute to uncontrolled hyperplasia. In models of gastrointestinal inflammation, increased cell numbers indicate enhanced normal repair processes. In healthy mice, orally administered EO increased Ki-67 expression in crypt cells compared to water-treated controls, contributing to increased cell number and crypt depth. This effect was attenuated by EO cessation, where cells returned to normal dynamics and kinetics. Overall, the results indicate the potential for EO to promote normal intestinal repair processes.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>23845</offset><text>Anti-Inflammatory Properties of Emu Oil</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>23885</offset><text>Myeloperoxidase (MPO) activity is a marker of neutrophil infiltration and thus an indicator of acute inflammation. In DSS-colitic mice, MPO activity was elevated, although not attenuated by EO. However, in a rat model of acetic-acid-induced colitis, EO administration significantly reduced MPO activity and TNF-α expression in the colon following EO treatment. More recently, EO treatment decreased MPO activity in acute DSS-induced colitic mice compared to DSS controls. As acute experimental colitis initiates a T-helper (Th1) response and chronic colitis incorporates both Th1 and Th2 pathways, analysing proinflammatory cytokines including IL-6, IL-8, IL-13, and IL-18 in comparison with MPO is beneficial in chronic models. The plasma levels of these cytokines following EO administration have not been widely assessed. Analysis of peripheral blood mononuclear cells may also be useful to understand how EO may modulate cellular mechanisms in the immune response. Additionally, MPO levels were decreased in rats with 5-FU-induced mucositis following oral administration of EO alone, EO combined with Lyprinol (a marine lipid extract derived from New Zealand green-lipped mussel [Perna canaliculus]), and olive oil within the jejunum, mid-small intestine, and ileum. The high oleic acid profile in EO, olive oil, and Lyprinol was likely to have contributed to the reduced MPO activity in mucositis. Additionally, EO significantly reduced MPO levels in Crohn’s-like colitis compared to diseased controls by the end of the trial (day 9).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>25429</offset><text>In acetic acid-induced colitic rats, EO elevated levels of catalase, superoxide dismutase, and glutathione peroxidase activity, which are natural antioxidant defences in the intestine. The expression of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor linked to anti-inflammatory responses, is decreased in UC patients; however, EO significantly increased the expression of PPARγ comparable to that of healthy animals.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>25884</offset><text>Although numerous animal studies have investigated the therapeutic effects of EO, several organic and methodological limitations should be considered when interpreting these findings. Many studies have used relatively small rodent numbers (often justified by ethical or methodological constraints, even when sample size calculations were performed), short treatment durations, and varying formulations of EO. Moreover, most studies have only utilised female mice, limiting generalisability and the detection of subtle effects or sex-related differences. Previous studies have also primarily focused on evaluating disease indicators and the mode of EO action; more detailed mechanistic examinations of gut microbiota, oxidative stress, epithelial barrier integrity and liver or kidney toxicity are warranted. Lastly, while some studies have tested EO doses ranging from 80 μL to 1 mL, these doses cannot be directly extrapolated to humans due to markedly different rates of absorption and physiological responses.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>26898</offset><text>Interestingly, in a study investigating atherogenic plaque formation in cafeteria diet-induced obese rats, EO reduced C-reactive protein levels, a common inflammatory marker increased in inflammatory conditions, including IBD. EO additionally lowered low-density lipoprotein (LDL)-cholesterol levels in a dose-dependent manner, preventing plaque formation. Furthermore, obese animals with increased LDL-cholesterol levels had decreased testosterone and increased luteinizing hormone (LH) levels, which have been shown to increase the incidence of cardiovascular diseases. Upon oral administration of EO, the levels of testosterone were increased and LH levels reduced, close to the normal range, in a dose-dependent manner. Overall, this demonstrated the systemic effect exerted by EO in managing pathological inflammatory diseases, which may be useful in IBD management.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>27770</offset><text>Influence of Emu Oil Constituents in Clinical Trials of IBD</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>27830</offset><text>Currently, there are no clinical trials of orally administered EO in IBD. However, IBD clinical studies involving the supplementation of certain FAs that are also found in EO have demonstrated promising findings. A pilot study by Prossomariti et al. (2017) demonstrated that 2 g/day of EPA (n-3) as a free fatty acid (FFA) supplement for 90 days partly altered microbiota populations in UC patients by increasing Porphyromonadaceae genus Parabacteroides, which are known to be decreased in UC. EPA-FFA supplementation additionally decreased Clostridium spp. and the Bacteroides genus. Moreover, a reduction in endoscopic and histological inflammation and an increase in goblet cell differentiation were observed. Indeed, following EPA-FFA supplementation, there was a concomitant significant upregulation of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signalling 3 mRNA expression, which is typically decreased in IBD patients compared to healthy individuals. Scaioli et al. substantiated the benefits of EPA, demonstrating its ability to significantly reduce faecal calprotectin levels and prevent symptomatic relapse in UC patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>28985</offset><text>Translation of dietary FA supplementation into human IBD populations has been inconsistent, with several sizeable randomised controlled trials of FAs failing to show clear benefits in maintaining remission. In a double-blind randomised, placebo-controlled trial by Middleton et al., essential FA supplementation (tablets containing γ-linolenic acid [1.6 g/day], DHA [n-3; 0.045 g/day], and EPA [0.27 g/day]) did not prolong the period of disease remission in quiescent UC compared to sunflower oil placebo. Similar results have been observed in a randomised controlled trial by Feagan et al., studying EPA and DHA as an FFA (4 g/day) encapsulated capsule, whereby the FFA was also not effective for the prevention of relapse in quiescent CD. However, in patients with active distal proctocolitis, fish extract (containing EPA 3.2 g/day and DHA 2.4 g/day) suppressed natural cytotoxicity and reduced disease activity. To address these discrepancies, future studies should employ standardised, high-dose FA formulations with clearly defined disease activity states, mechanistic endpoints, and dietary controls to accurately determine their therapeutic potential in IBD.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>30157</offset><text>A double-blind controlled study by Bueno-Hernández et al., where patients with mild to moderate UC received 720 mg/day of orally administered cis-palmitoleic acid (n-7) for 8 weeks, displayed a downregulation of proinflammatory IL-6 expression and upregulation of hepatocyte nuclear factor 4 γ (HNF4γ) and HNF4α gene expression. HNFAγ and particularly HNF4α are reduced in UC patients compared to healthy individuals. Furthermore, orally administered cis-palmitoleic acid improved clinical parameters of disease, including blood in stool and general well-being. Oleic acid (n-9), present in high amounts in olive oil and the predominant triglyceride in EO, has not been investigated in the clinical setting of IBD. However, prospective cohort studies have demonstrated that oleic acid is inversely associated with UC development in a dose-dependent manner. Notably, linoleic acid (n-6) increases the risk of IBD, though linoleic acid has demonstrated both a pro-inflammatory and anti-inflammatory effect. Additional experimental and clinical trials of individual FA supplementation in IBD, particularly in CD, may assist in elucidating the potential role for EO in the management of gastrointestinal inflammation. These inconsistent findings underscore the need for cautious interpretation of preclinical findings and highlight the importance of conducting well-designed clinical trials to determine whether EO can exert clinically meaningful effects in IBD cohorts.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>31644</offset><text>Potential Mechanisms of Emu Oil Action</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>31683</offset><text>Fatty Acids</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>31695</offset><text>There are several plausible molecular mechanisms to explain the anti-inflammatory capabilities of FAs in EO; however, they are yet to be fully elucidated. It is known that n-6 FAs such as arachidonic acid (AA) from cell membranes metabolise into eicosanoid mediators, including thromboxane B2, prostaglandin E2, and leukotriene B4, which are proinflammatory. Nishida et al. observed increased AA and decreased oleic acid composition in the phospholipid membrane of patients with active UC compared to healthy controls, potentially enhancing AA metabolism. Dietary intake of AA has also been shown to increase AA content in the cell membrane, subsequently increasing AA-derived lipid mediator production. Nonetheless, reducing AA metabolites may be facilitated by ingesting anti-inflammatory FAs such as those in EO. Metabolism of n-3 FAs produces prostaglandin E3 and leukotriene B5, which possess significantly reduced proinflammatory activity in comparison to other eicosanoids derived from n-6 FAs. The complexities of the overall anti-inflammatory or proinflammatory effect observed in FAs in EO must be explored to understand its overall mechanism of action in intestinal inflammatory conditions. Future studies would benefit from conducting red blood cell membrane FA composition analysis via FA methyl ester preparation and gas chromatography to observe if orally administered EO increases the incorporation of certain FAs in cell membranes.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>33144</offset><text>Non-Triglyceride Fraction</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>33170</offset><text>The antioxidant and anti-inflammatory properties of EO cannot be explained solely by its FA profile; compounds within the non-triglyceride fraction may provide additional therapeutic benefits. However, current studies have not yet identified the specific chemical forms of carotenoids, flavones, polyphenols, phospholipids, and tocopherols that comprise the non-triglyceride fraction of EO. This is likely due to the fraction being extremely low in concentration, rendering it analytically challenging to detect and quantify minor compounds. Furthermore, processing, diet of the emu and refining methods may degrade or remove many of these compounds, further contributing to the difficulty of detection. Therefore, ascertaining the effect that these specific compounds may have in IBD remains complex. Improved characterisation of the non-triglyceride fraction should further elucidate the clinical relevance of EO in IBD. Although the non-triglyceride fraction has not been clearly defined, the potential effects of various bioactive compounds under carotenoids, flavones, polyphenols, and tocopherols can be observed in IBD studies. For instance, a mouse model of DSS colitis with oral treatment of the hydroalcoholic extract of Tagetes erecta L., a flower rich in the carotenoid lutein, improved the natural antioxidant defence by increased glutathione levels, catalase activity and normalising superoxide dismutase and glutathione-s-transferase activities. Carotenoids have also been shown to alleviate DSS colitis in mice by reducing proinflammatory markers and suppressing bilophila and mucispirillium, which are associated with inflammation, while upregulating tight junction proteins, strengthening the intestinal barrier.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>34901</offset><text>Tocopherols are consistently listed among the minor constituents of EO, although the isomeric forms have not been well characterised. However, a single study demonstrated the presence of α-tocopherol in EO. α-Tocopherol may protect against ferroptosis and oxidative tissue injury, while also exerting antioxidant-independent effects such as modulation of inflammatory gene expression (NF-kB signalling) and cholesterol metabolism, which could influence immune responses and epithelial integrity in IBD. In a mouse model of DSS-induced colitis, α-tocopherol inhibited colitis-induced loss of the tight junction protein occludin. Furthermore, α-tocopherol attenuated colitis-caused lipopolysaccharide-binding protein in plasma, a surrogate marker of intestinal barrier dysfunction, mitigated DSS-caused faecal bleeding, diarrhoea, and elevation of IL-6.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>35769</offset><text>Polyphenols and flavones (the largest polyphenol subgroup) are secondary plant metabolites. Like tocopherols and carotenoids, polyphenols and flavones in EO are likely sourced from dietary transfer, though smaller trace amounts may be stored in tissue and fat as they are less fat soluble. The potential mechanism of polyphenols and flavones primarily involves the blockade of various signalling pathways, including TLR4/MyD88/NF-kB, MAPKs, PI3K/AKT, and NLRP3 inflammasome, which regulate the intestinal microflora and Treg/Th17 balance, decreasing inflammatory responses and oxidative stress and increasing tight junction expression.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>36405</offset><text>Terpenes are plant metabolites that have also been recently detected in some EO batches. Terpenes have demonstrated the ability to prevent oxidative stress, combat dysbiosis, restore intestinal permeability, and inhibit the inflammatory process in different signalling pathways. In mouse models of IBD, different forms of terpenes have demonstrated the ability to downregulate inflammatory cytokines IL-1β, IL-6, IL-13, and TNF-α in tissue and to reduce histological damage and lesion severity scores. Nevertheless, the presence of other constituents of the non-triglyceride fraction, such as vitamin K, appears anecdotal as no peer-reviewed publications have yet confirmed their presence. Additionally, the role of phospholipids in EO has not been explored. This highlights the need for comprehensive compositional profiling of the non-triglyceride fraction to validate and quantify these bioactive constituents. Investigations into the non-triglyceride fraction isolates in IBD would additionally reveal their therapeutic activity and hence the potential of utilising EO in IBD. Moreover, vitamin D, which is present in EO, has been shown to inhibit the production of Th17 and proinflammatory cytokine IL-17 by restraining NF-kB signalling. Overall, there is likely a concurrent effect of the non-triglyceride and triglyceride fractions on therapeutic efficacy. However, since the non-triglyceride fraction is present only in trace amounts, the cumulative influence in IBD is presumably modest or negligible. Improving the efficacy of EO may therefore rely on maximising the composition of the non-triglyceride fraction, which could be achieved through altering emu feed and processing methodologies.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>38115</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>38127</offset><text>Although several therapeutic options are available to IBD sufferers, their use remains variably effective and is associated with the risk of serious side effects, including pancreatitis, cardiotoxicity, and malignancy. Preclinical studies suggest that EO may offer some therapeutic benefit in IBD treatment. However, factors that contribute to heterogeneity in EO composition, including emu feed, environment, and genetics, need to be addressed by standardisation of extraction methods and further research into sample variability. Moreover, comprehensive pharmacological investigations examining the pharmacokinetic and pharmacodynamic properties of EO are warranted to inform safe and effective dosing strategies, clarify its mechanism of action, and facilitate innovations to improve bioavailability. It is important to note that there are currently no published clinical trials that investigate the efficacy or safety of orally administered EO. Observations from FA supplementation trials in IBD highlight the challenges of translating such findings into meaningful clinical application. Therefore, although promising, EO cannot presently be positioned as a clinically relevant adjunct therapy for IBD. In future, well-designed clinical trials will be essential to determine the true translational value of EO for inflammatory disorders affecting the digestive tract.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>39499</offset><text>Acknowledgments</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>39515</offset><text>The authors wish to acknowledge the Traditional Owners and Custodians of the lands on which this research was undertaken and recognise Aboriginal healing and knowledge systems regarding the use of emu oil. No generative AI and AI-assisted technologies have been used in the preparation of this work.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>39815</offset><text>Conflict of Interest Statement</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>39846</offset><text>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>40017</offset><text>Funding Sources</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>40033</offset><text>The authors did not receive financial support for the research, authorship, and/or publication of this article.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>40145</offset><text>Author Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>40166</offset><text>S.N.M. contributed to the conceptualisation, investigation, and original drafting of this literature review. S.M. and G.S.H. contributed to the conceptualisation, review and editing of the manuscript.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>40367</offset><text>References</text></passage><passage><infon key="fpage">1526</infon><infon key="issue">2</infon><infon key="pub-id_pmid">36675038</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2023</infon><offset>40378</offset><text>Pathophysiology of inflammatory bowel disease: innate immune system</text></passage><passage><infon key="fpage">23</infon><infon key="issue">1</infon><infon key="pub-id_pmid">33160400</infon><infon key="section_type">REF</infon><infon key="source">Biol Direct</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2020</infon><offset>40446</offset><text>Pathophysiology of crohn's disease inflammation and recurrence</text></passage><passage><infon key="fpage">1756</infon><infon key="issue">10080</infon><infon key="lpage">70</infon><infon key="pub-id_pmid">27914657</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">389</infon><infon key="year">2017</infon><offset>40509</offset><text>Ulcerative colitis</text></passage><passage><infon key="fpage">459</infon><infon key="issue">60</infon><infon key="lpage">67</infon><infon key="pub-id_pmid">21616044</infon><infon key="section_type">REF</infon><infon key="source">Discov Med</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2011</infon><offset>40528</offset><text>Cytokines in the pathogenesis of ulcerative colitis</text></passage><passage><infon key="fpage">231</infon><infon key="issue">2</infon><infon key="lpage">5</infon><infon key="pub-id_pmid">24938525</infon><infon key="section_type">REF</infon><infon key="source">Immunol Lett</infon><infon key="type">ref</infon><infon key="volume">161</infon><infon key="year">2014</infon><offset>40580</offset><text>Inflammatory bowel disease</text></passage><passage><infon key="fpage">1053</infon><infon key="issue">11</infon><infon key="lpage">60</infon><infon key="pub-id_pmid">26414706</infon><infon key="section_type">REF</infon><infon key="source">JAMA Pediatr</infon><infon key="type">ref</infon><infon key="volume">169</infon><infon key="year">2015</infon><offset>40607</offset><text>Inflammatory bowel disease in children and adolescents</text></passage><passage><infon key="fpage">63</infon><infon key="issue">1</infon><infon key="lpage">79</infon><infon key="pub-id_pmid">30466773</infon><infon key="section_type">REF</infon><infon key="source">Immunol Allergy Clin North Am</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2019</infon><offset>40662</offset><text>Early-onset inflammatory bowel disease</text></passage><passage><infon key="fpage">47</infon><infon key="issue">1</infon><infon key="lpage">65</infon><infon key="pub-id_pmid">33940007</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">161</infon><infon key="year">2021</infon><offset>40701</offset><text>Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists</text></passage><passage><infon key="fpage">12</infon><infon key="issue">1</infon><infon key="lpage">8</infon><infon key="pub-id_pmid">22847466</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr Gastroenterol Nutr</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2013</infon><offset>40846</offset><text>Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">12</infon><infon key="pub-id_pmid">37455149</infon><infon key="section_type">REF</infon><infon key="source">Cytokine Growth Factor Rev</infon><infon key="type">ref</infon><infon key="volume">71-72</infon><infon key="year">2023</infon><offset>40945</offset><text>Recent advances in the treatment of IBD: targets, mechanisms and related therapies</text></passage><passage><infon key="fpage">1733</infon><infon key="issue">11</infon><infon key="lpage">42</infon><infon key="pub-id_pmid">31833543</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2020</infon><offset>41028</offset><text>Antibiotic cocktail for pediatric acute severe colitis and the microbiome: the PRASCO randomized controlled trial</text></passage><passage><infon key="fpage">292</infon><infon key="issue">2</infon><infon key="lpage">310</infon><infon key="pub-id_pmid">30044358</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr Gastroenterol Nutr</infon><infon key="type">ref</infon><infon key="volume">67</infon><infon key="year">2018</infon><offset>41142</offset><text>Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the european Crohn's and colitis organization and the european society of paediatric gastroenterology, hepatology and nutrition</text></passage><passage><infon key="fpage">147</infon><infon key="issue">3</infon><infon key="lpage">59</infon><infon key="pub-id_pmid">32040250</infon><infon key="section_type">REF</infon><infon key="source">J Dig Dis</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2020</infon><offset>41387</offset><text>Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment</text></passage><passage><infon key="fpage">1</infon><infon key="issue">1</infon><infon key="lpage">8</infon><infon key="pub-id_pmid">17638122</infon><infon key="section_type">REF</infon><infon key="source">Inflammopharmacology</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1998</infon><offset>41464</offset><text>Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in Aboriginal medicine</text></passage><passage><infon key="fpage">155</infon><infon key="lpage">78</infon><infon key="pub-id_pmid">26462367</infon><infon key="section_type">REF</infon><infon key="source">Prog Drug Res</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2015</infon><offset>41558</offset><text>Traditional medicinal oils sourced from birds: anti-inflammatories and potential immunoregulants</text></passage><passage><infon key="fpage">135</infon><infon key="issue">1</infon><infon key="lpage">45</infon><infon key="pub-id_pmid">29214422</infon><infon key="section_type">REF</infon><infon key="source">Dig Dis Sci</infon><infon key="type">ref</infon><infon key="volume">63</infon><infon key="year">2018</infon><offset>41655</offset><text>Emu oil improves clinical indicators of disease in a mouse model of colitis-associated colorectal cancer</text></passage><passage><infon key="fpage">715</infon><infon key="issue">2</infon><infon key="lpage">23</infon><infon key="pub-id_pmid">33840308</infon><infon key="section_type">REF</infon><infon key="source">Nutr Cancer</infon><infon key="type">ref</infon><infon key="volume">74</infon><infon key="year">2022</infon><offset>41760</offset><text>Emu oil attenuates disease severity and results in fewer large colonic tumors in a mouse model of colitis-associated colorectal cancer</text></passage><passage><infon key="fpage">887</infon><infon key="issue">4</infon><infon key="lpage">96</infon><infon key="pub-id_pmid">22147247</infon><infon key="section_type">REF</infon><infon key="source">Dig Dis Sci</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2012</infon><offset>41895</offset><text>Emu oil increases colonic crypt depth in a rat model of ulcerative colitis</text></passage><passage><infon key="fpage">47</infon><infon key="issue">1</infon><infon key="lpage">56</infon><infon key="pub-id_pmid">25560991</infon><infon key="section_type">REF</infon><infon key="source">Inflammopharmacology</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2015</infon><offset>41970</offset><text>Modulation of PPARγ and TNFα by emu oil and glycyrrhizin in ulcerative colitis</text></passage><passage><infon key="fpage">273</infon><infon key="issue">3</infon><infon key="lpage">80</infon><infon key="pub-id_pmid">30907169</infon><infon key="section_type">REF</infon><infon key="source">Scand J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">2019</infon><offset>42057</offset><text>Emu oil reduces disease severity in a mouse model of chronic ulcerative colitis</text></passage><passage><infon key="fpage">1331</infon><infon key="issue">6</infon><infon key="lpage">45</infon><infon key="pub-id_pmid">37402926</infon><infon key="section_type">REF</infon><infon key="source">Biometals</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2023</infon><offset>42137</offset><text>Emu oil and zinc monoglycerolate independently reduce disease severity in a rat model of ulcerative colitis</text></passage><passage><infon key="fpage">187</infon><infon key="issue">2</infon><infon key="lpage">94</infon><infon key="pub-id_pmid">11233007</infon><infon key="section_type">REF</infon><infon key="source">Poult Sci</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">2001</infon><offset>42245</offset><text>Influence of two dietary fats on the composition of emu oil and meat</text></passage><passage><infon key="fpage">109595</infon><infon key="section_type">REF</infon><infon key="source">Lwt-food Sci Technol</infon><infon key="type">ref</infon><infon key="volume">130</infon><infon key="year">2020</infon><offset>42314</offset><text>Molecular formation mechanism of trans linolenic acid in thermally induced α-linolenic acid</text></passage><passage><infon key="fpage">1305</infon><infon key="issue">11</infon><infon key="lpage">17</infon><infon key="pub-id_pmid">24047797</infon><infon key="section_type">REF</infon><infon key="source">Exp Biol Med (Maywood)</infon><infon key="type">ref</infon><infon key="volume">238</infon><infon key="year">2013</infon><offset>42410</offset><text>Emu oil expedites small intestinal repair following 5-fluorouracil-induced mucositis in rats</text></passage><passage><infon key="fpage">55</infon><infon key="pub-id_pmid">26852336</infon><infon key="section_type">REF</infon><infon key="source">BMC Complement Altern Med</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2016</infon><offset>42503</offset><text>Emu oil offers protection in crohn's disease model in rats</text></passage><passage><infon key="fpage">945</infon><infon key="issue">11</infon><infon key="lpage">52</infon><infon key="pub-id_pmid">29985049</infon><infon key="section_type">REF</infon><infon key="source">Exp Biol Med (Maywood)</infon><infon key="type">ref</infon><infon key="volume">243</infon><infon key="year">2018</infon><offset>42562</offset><text>Intestinal homeostasis is restored in mice following a period of intestinal growth induced by orally administered emu oil</text></passage><passage><infon key="fpage">1697</infon><infon key="issue">18</infon><infon key="lpage">707</infon><infon key="pub-id_pmid">32903038</infon><infon key="section_type">REF</infon><infon key="source">Exp Biol Med (Maywood)</infon><infon key="type">ref</infon><infon key="volume">245</infon><infon key="year">2020</infon><offset>42684</offset><text>Orally administered Emu Oil attenuates disease in a mouse model of crohn's-like colitis</text></passage><passage><infon key="fpage">202</infon><infon key="issue">2</infon><infon key="lpage">9</infon><infon key="pub-id_pmid">32940671</infon><infon key="section_type">REF</infon><infon key="source">Carcinogenesis</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2021</infon><offset>42772</offset><text>Emu Oil and grape seed extract reduce tumour burden and disease parameters in murine colitis-associated colorectal cancer</text></passage><passage><infon key="fpage">1345</infon><infon key="issue">10</infon><infon key="lpage">50</infon><infon key="section_type">REF</infon><infon key="source">Aust J Exp Agric</infon><infon key="type">ref</infon><infon key="volume">48</infon><infon key="year">2008</infon><offset>42894</offset><text>Comparison of the antioxidant properties of Emu Oil with other avian oils</text></passage><passage><infon key="fpage">857</infon><infon key="issue">5</infon><infon key="lpage">61</infon><infon key="pub-id_pmid">22369065</infon><infon key="section_type">REF</infon><infon key="source">J Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2012</infon><offset>42968</offset><text>Emu Oil: a novel therapeutic for disorders of the gastrointestinal tract?</text></passage><passage><infon key="fpage">132965</infon><infon key="pub-id_pmid">35429940</infon><infon key="section_type">REF</infon><infon key="source">Food Chem</infon><infon key="type">ref</infon><infon key="volume">387</infon><infon key="year">2022</infon><offset>43042</offset><text>Vitamin D composition of Australian game products</text></passage><passage><infon key="fpage">127</infon><infon key="issue">2</infon><infon key="lpage">32</infon><infon key="pub-id_pmid">17694361</infon><infon key="section_type">REF</infon><infon key="source">Inflammopharmacology</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1997</infon><offset>43092</offset><text>Anti-inflammatory activity of Emu Oils in rats</text></passage><passage><infon key="fpage">17</infon><infon key="issue">Suppl 2</infon><infon key="section_type">REF</infon><infon key="source">J Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2014</infon><offset>43139</offset><text>Emu oil source does not significantly alter therapeutic efficacy, while ostrich oil has no beneficial effect, in a rat model of chemotherapy-induced mucositis</text></passage><passage><infon key="fpage">780</infon><infon key="issue">6</infon><infon key="lpage">5</infon><infon key="section_type">REF</infon><infon key="source">Eur J Lipid Sci Technol</infon><infon key="type">ref</infon><infon key="volume">113</infon><infon key="year">2011</infon><offset>43298</offset><text>Evaluation of Emu Oil extraction methods and their effects on physical and rheological behavior</text></passage><passage><infon key="fpage">102050</infon><infon key="issue">10</infon><infon key="pub-id_pmid">35952603</infon><infon key="section_type">REF</infon><infon key="source">Poult Sci</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2022</infon><offset>43394</offset><text>Carcass traits and fat quality of breeding emu (Dromaius novaehollandiae) in Northern Japan</text></passage><passage><infon key="fpage">11082</infon><infon key="issue">1</infon><infon key="pub-id_pmid">32632331</infon><infon key="section_type">REF</infon><infon key="source">Sci Rep</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2020</infon><offset>43486</offset><text>The influence of age and gender on emu (Dromaius novaehollandiae) fat</text></passage><passage><infon key="fpage">279</infon><infon key="lpage">92</infon><infon key="section_type">REF</infon><infon key="source">Polyphenols: prevention and treatment of human disease</infon><infon key="type">ref</infon><infon key="year">2018</infon><offset>43556</offset><text>Chapter 23 - antioxidants and polyphenols in inflammatory bowel disease: ulcerative colitis and crohn disease</text></passage><passage><infon key="fpage">603</infon><infon key="issue">6</infon><infon key="lpage">7</infon><infon key="pub-id_pmid">12934669</infon><infon key="section_type">REF</infon><infon key="source">Lipids</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">2003</infon><offset>43666</offset><text>Antagonism of croton oil inflammation by topical Emu Oil in CD-1 mice</text></passage><passage><infon key="fpage">2238</infon><infon key="issue">11</infon><infon key="pub-id_pmid">35684037</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2022</infon><offset>43736</offset><text>Chemical characterization and in vivo toxicological safety evaluation of Emu oil</text></passage><passage><infon key="section_type">REF</infon><infon key="source">Emu Oil Capsules</infon><infon key="type">ref</infon><infon key="year">2025</infon><offset>43817</offset><text>Adelaide (Australia): Emu tracks</text></passage><passage><infon key="fpage">1157</infon><infon key="issue">7</infon><infon key="lpage">72</infon><infon key="pub-id_pmid">36926666</infon><infon key="section_type">REF</infon><infon key="source">World J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2023</infon><offset>43850</offset><text>Mucosal healing and inflammatory bowel disease: therapeutic implications and new targets</text></passage><passage><infon key="fpage">S148</infon><infon key="issue">1</infon><infon key="section_type">REF</infon><infon key="source">Burns</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">2007</infon><offset>43939</offset><text>Consequences of burn injuries treatment with 100% pure emu oil</text></passage><passage><infon key="fpage">407</infon><infon key="issue">4</infon><infon key="lpage">10</infon><infon key="pub-id_pmid">15837639</infon><infon key="section_type">REF</infon><infon key="source">Di Yi Jun Yi Da Xue Xue Bao</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2005</infon><offset>44002</offset><text>Anti-inflammatory activity and healing-promoting effects of topical application of Emu Oil on wound in scalded rats</text></passage><passage><infon key="fpage">2288</infon><infon key="issue">9</infon><infon key="lpage">96</infon><infon key="pub-id_pmid">26217022</infon><infon key="section_type">REF</infon><infon key="source">Poult Sci</infon><infon key="type">ref</infon><infon key="volume">94</infon><infon key="year">2015</infon><offset>44118</offset><text>Ratite oils promote keratinocyte cell growth and inhibit leukocyte activation</text></passage><passage><infon key="fpage">6419216</infon><infon key="pub-id_pmid">27069472</infon><infon key="section_type">REF</infon><infon key="source">Dermatol Res Pract</infon><infon key="type">ref</infon><infon key="volume">2016</infon><infon key="year">2016</infon><offset>44196</offset><text>Effects of topical Emu Oil on burn wounds in the skin of balb/c mice</text></passage><passage><infon key="fpage">2404</infon><infon key="issue">7</infon><infon key="lpage">7</infon><infon key="pub-id_pmid">9858176</infon><infon key="section_type">REF</infon><infon key="source">Plast Reconstr Surg</infon><infon key="type">ref</infon><infon key="volume">102</infon><infon key="year">1998</infon><offset>44265</offset><text>Promotion of second intention wound healing by Emu Oil lotion: comparative results with furasin, polysporin, and cortisone</text></passage><passage><infon key="fpage">10</infon><infon key="pub-id_pmid">25625116</infon><infon key="section_type">REF</infon><infon key="source">Adv Biomed Res</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2015</infon><offset>44388</offset><text>Evaluation of the clinical efficacy and safety of an eye counter pad containing caffeine and vitamin K in emulsified Emu Oil base</text></passage><passage><infon key="fpage">10</infon><infon key="issue">1</infon><infon key="lpage">3</infon><infon key="section_type">REF</infon><infon key="source">J Evid Based Complement Altern Med</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2016</infon><offset>44518</offset><text>Efficacy of topical application of Emu Oil on areola skin barrier in breastfeeding women</text></passage><passage><infon key="fpage">112706</infon><infon key="pub-id_pmid">39032473</infon><infon key="section_type">REF</infon><infon key="source">Int Immunopharmacol</infon><infon key="type">ref</infon><infon key="volume">139</infon><infon key="year">2024</infon><offset>44607</offset><text>Emu Oil alleviates atopic dermatitis-like responses by inhibiting Cdc42 signaling of keratinocyte</text></passage><passage><infon key="fpage">106283</infon><infon key="section_type">REF</infon><infon key="source">J Funct Foods</infon><infon key="type">ref</infon><infon key="volume">119</infon><infon key="year">2024</infon><offset>44705</offset><text>Emu Oil enhances cutaneous wound healing by modulating inflammation through promoting macrophage M2 polarization via MAPK signaling pathway</text></passage><passage><infon key="fpage">1171</infon><infon key="issue">7</infon><infon key="lpage">80</infon><infon key="pub-id_pmid">27618153</infon><infon key="section_type">REF</infon><infon key="source">Nutr Cancer</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2016</infon><offset>44845</offset><text>Emu Oil combined with lyprinol™ reduces small intestinal damage in a rat model of chemotherapy-induced mucositis</text></passage><passage><infon key="fpage">513</infon><infon key="issue">4</infon><infon key="lpage">9</infon><infon key="pub-id_pmid">20377926</infon><infon key="section_type">REF</infon><infon key="source">Br J Nutr</infon><infon key="type">ref</infon><infon key="volume">104</infon><infon key="year">2010</infon><offset>44960</offset><text>Orally administered Emu Oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis</text></passage><passage><infon key="fpage">199</infon><infon key="issue">2</infon><infon key="lpage">206</infon><infon key="pub-id_pmid">30862196</infon><infon key="section_type">REF</infon><infon key="source">Nutr Cancer</infon><infon key="type">ref</infon><infon key="volume">71</infon><infon key="year">2019</infon><offset>45093</offset><text>Combined nutraceuticals: a novel approach to colitis-associated colorectal cancer?</text></passage><passage><infon key="fpage">39</infon><infon key="lpage">45</infon><infon key="pub-id_pmid">30653951</infon><infon key="section_type">REF</infon><infon key="source">Clin Chim Acta</infon><infon key="type">ref</infon><infon key="volume">491</infon><infon key="year">2019</infon><offset>45176</offset><text>Ki-67 protein as a tumour proliferation marker</text></passage><passage><infon key="fpage">102567</infon><infon key="issue">Suppl 2</infon><infon key="section_type">REF</infon><infon key="source">Curr Dev Nutr</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2024</infon><offset>45223</offset><text>Orally-Administered emu oil reduces proximal colonic Crypt Hyperplasia in a murine model of colitis-associated colorectal cancer</text></passage><passage><infon key="fpage">15</infon><infon key="issue">1</infon><infon key="lpage">23</infon><infon key="section_type">REF</infon><infon key="source">Aust J Herb Naturop Med</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2020</infon><offset>45352</offset><text>Mucosal stimulation following oral administration of Emu Oil represents a process of normal intestinal growth in rats</text></passage><passage><infon key="fpage">279</infon><infon key="issue">4</infon><infon key="lpage">88</infon><infon key="pub-id_pmid">25177159</infon><infon key="section_type">REF</infon><infon key="source">Korean J Physiol Pharmacol</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2014</infon><offset>45470</offset><text>A review on chemical-induced inflammatory bowel disease models in rodents</text></passage><passage><infon key="fpage">3063</infon><infon key="issue">9</infon><infon key="lpage">8</infon><infon key="pub-id_pmid">26415675</infon><infon key="section_type">REF</infon><infon key="source">J Sci Food Agric</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">2016</infon><offset>45544</offset><text>Emu Oil decreases atherogenic plaque formation in cafeteria diet-induced obese rats</text></passage><passage><infon key="fpage">395</infon><infon key="issue">6</infon><infon key="lpage">406</infon><infon key="section_type">REF</infon><infon key="source">Nutr Res (New York, Ny)</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2004</infon><offset>45628</offset><text>Comparative effects of emu and olive oil on aortic early atherosclerosis and associated risk factors in hypercholesterolemic hamsters</text></passage><passage><infon key="fpage">7458</infon><infon key="issue">1</infon><infon key="pub-id_pmid">28785079</infon><infon key="section_type">REF</infon><infon key="source">Sci Rep</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2017</infon><offset>45762</offset><text>Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis</text></passage><passage><infon key="fpage">1268</infon><infon key="issue">8</infon><infon key="lpage">75.e2</infon><infon key="pub-id_pmid">29391271</infon><infon key="section_type">REF</infon><infon key="source">Clin Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2018</infon><offset>45927</offset><text>Eicosapentaenoic acid reduces fecal levels of calprotectin and prevents relapse in patients with ulcerative colitis</text></passage><passage><infon key="fpage">1131</infon><infon key="issue">6</infon><infon key="lpage">5</infon><infon key="pub-id_pmid">12030955</infon><infon key="section_type">REF</infon><infon key="source">Aliment Pharmacol Ther</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2002</infon><offset>46043</offset><text>A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis</text></passage><passage><infon key="fpage">1690</infon><infon key="issue">14</infon><infon key="lpage">7</infon><infon key="pub-id_pmid">18398081</infon><infon key="section_type">REF</infon><infon key="source">Jama</infon><infon key="type">ref</infon><infon key="volume">299</infon><infon key="year">2008</infon><offset>46190</offset><text>Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials</text></passage><passage><infon key="fpage">804</infon><infon key="issue">5</infon><infon key="lpage">9</infon><infon key="pub-id_pmid">9625132</infon><infon key="section_type">REF</infon><infon key="source">Am J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">1998</infon><offset>46304</offset><text>Distal procto-colitis, natural cytotoxicity, and essential fatty acids</text></passage><passage><infon key="fpage">257</infon><infon key="issue">3</infon><infon key="lpage">63</infon><infon key="pub-id_pmid">28185444</infon><infon key="section_type">REF</infon><infon key="source">Minerva Gastroenterol Dietol</infon><infon key="type">ref</infon><infon key="volume">63</infon><infon key="year">2017</infon><offset>46375</offset><text>Effect of cis-palmitoleic acid supplementation on inflammation and expression of HNF4γ, HNF4α and IL6 in patients with ulcerative colitis</text></passage><passage><infon key="fpage">11</infon><infon key="issue">1</infon><infon key="lpage">8</infon><infon key="pub-id_pmid">24216567</infon><infon key="section_type">REF</infon><infon key="source">Eur J Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2014</infon><offset>46521</offset><text>Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries</text></passage><passage><infon key="fpage">1505s</infon><infon key="issue">6 Suppl l</infon><infon key="lpage">19s</infon><infon key="pub-id_pmid">16841861</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Nutr</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">2006</infon><offset>46647</offset><text>n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases</text></passage><passage><infon key="fpage">1002</infon><infon key="issue">8</infon><infon key="lpage">7</infon><infon key="pub-id_pmid">3117625</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">1987</infon><offset>46720</offset><text>Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis</text></passage><passage><infon key="fpage">41</infon><infon key="lpage">8</infon><infon key="pub-id_pmid">29610056</infon><infon key="section_type">REF</infon><infon key="source">Prostaglandins Leukot Essent Fatty Acids</infon><infon key="type">ref</infon><infon key="volume">132</infon><infon key="year">2018</infon><offset>46839</offset><text>Omega-6 fatty acids and inflammation</text></passage><passage><infon key="fpage">95</infon><infon key="lpage">106</infon><infon key="pub-id_pmid">30979660</infon><infon key="section_type">REF</infon><infon key="source">Nutr Res</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">2019</infon><offset>46876</offset><text>Hydroalcoholic extract of Tagetes erecta L. flowers, rich in the carotenoid lutein, attenuates inflammatory cytokine secretion and improves the oxidative stress in an animal model of ulcerative colitis</text></passage><passage><infon key="fpage">6101</infon><infon key="issue">15</infon><infon key="lpage">14</infon><infon key="pub-id_pmid">40626912</infon><infon key="section_type">REF</infon><infon key="source">Food Funct</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2025</infon><offset>47078</offset><text>Comparison of four characteristic carotenoids (lutein, β-carotene, lycopene, and astaxanthin) in alleviating DSS-induced colitis through gut microbiota regulation</text></passage><passage><infon key="fpage">108327</infon><infon key="issue">4</infon><infon key="pub-id_pmid">39978678</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">301</infon><infon key="year">2025</infon><offset>47244</offset><text>Antioxidant-independent activities of alpha-tocopherol</text></passage><passage><infon key="fpage">180</infon><infon key="lpage">9</infon><infon key="pub-id_pmid">33352218</infon><infon key="section_type">REF</infon><infon key="source">Free Radic Biol Med</infon><infon key="type">ref</infon><infon key="volume">163</infon><infon key="year">2021</infon><offset>47299</offset><text>Vitamin E alpha- and gamma-tocopherol mitigate colitis, protect intestinal barrier function and modulate the gut microbiota in mice</text></passage><passage><infon key="fpage">2090</infon><infon key="issue">7</infon><infon key="pub-id_pmid">33917379</infon><infon key="section_type">REF</infon><infon key="source">Molecules</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2021</infon><offset>47431</offset><text>Gastroprotective effects of polyphenols against various gastro-intestinal disorders: a mini-review with special focus on clinical evidence</text></passage><passage><infon key="fpage">1168990</infon><infon key="pub-id_pmid">37324477</infon><infon key="section_type">REF</infon><infon key="source">Front Pharmacol</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2023</infon><offset>47570</offset><text>Natural flavones from edible and medicinal plants exhibit enormous potential to treat ulcerative colitis</text></passage><passage><infon key="fpage">1561</infon><infon key="issue">4</infon><infon key="section_type">REF</infon><infon key="source">J Cardiovasc Dis Res</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2021</infon><offset>47675</offset><text>Systematic analysis of Emu Oil</text></passage><passage><infon key="fpage">5430</infon><infon key="issue">22</infon><infon key="pub-id_pmid">33233487</infon><infon key="section_type">REF</infon><infon key="source">Molecules</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2020</infon><offset>47706</offset><text>Intestinal anti-inflammatory activity of terpenes in experimental models (2010-2020): a review</text></passage><passage><infon key="fpage">1</infon><infon key="issue">1</infon><infon key="lpage">7</infon><infon key="section_type">REF</infon><infon key="source">Folia Biol</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">2008</infon><offset>47801</offset><text>Effects of borneol and thymoquinone on TNBS-induced colitis in mice</text></passage><passage><infon key="fpage">81</infon><infon key="lpage">9</infon><infon key="pub-id_pmid">26875635</infon><infon key="section_type">REF</infon><infon key="source">Eur J Pharmacol</infon><infon key="type">ref</infon><infon key="volume">776</infon><infon key="year">2016</infon><offset>47869</offset><text>Nerol alleviates pathologic markers in the oxazolone-induced colitis model</text></passage><passage><infon key="fpage">108456</infon><infon key="lpage">6</infon><infon key="pub-id_pmid">37247693</infon><infon key="section_type">REF</infon><infon key="source">Pharmacol Ther</infon><infon key="type">ref</infon><infon key="volume">248</infon><infon key="year">2023</infon><offset>47944</offset><text>Terpenes: modulating anti-inflammatory signaling in inflammatory bowel disease</text></passage><passage><infon key="fpage">322</infon><infon key="issue">6</infon><infon key="lpage">3</infon><infon key="pub-id_pmid">27147490</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2016</infon><offset>48023</offset><text>IBD: Vitamin D and IBD: moving towards clinical trials</text></passage></document>
</collection>